Takeda Tests New Highs, But Struggles To Find Entyvio Successor

Core Insights - Takeda Pharmaceutical Company Limited (TAK) was previously discussed in May, indicating a challenging outlook for 2025 [1] Company Overview - The stock of Takeda was significantly undervalued at the time of the last analysis, suggesting potential for recovery [1] Analyst Background - The analysis is conducted by an experienced analyst with over 20 years in foreign policy research and 25 years in investment analysis, focusing on value plays [1]